The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Reshed'ko G.K.

GBOU VPO "Smolenskaia gosudarstvennaia meditsinskaia akademiia" Minzdravsotsrazvitiia Rossii

Khaĭkina E.V.

GBOU VPO "Smolenskaia gosudarstvennaia meditsinskaia akademiia" Minzdravsotsrazvitiia Rossii

The clinical application of glibenclamide: the problem of safety and efficacy

Authors:

Reshed'ko G.K., Khaĭkina E.V.

More about the authors

Journal: Problems of Endocrinology. 2012;58(3): 65‑69

Views: 834

Downloaded: 15

Download PDF (RU)
Contact the author
Table of contents

THE CLINICAL APPLICATION OF GLIBENCLAMIDE: THE PROBLEM OF SAFETY AND EFFICACY
THE CLINICAL APPLICATION OF GLIBENCLAMIDE: THE PROBLEM OF SAFETY AND EFFICACY

To cite this article:

Reshed'ko GK, Khaĭkina EV. The clinical application of glibenclamide: the problem of safety and efficacy. Problems of Endocrinology. 2012;58(3):65‑69. (In Russ.)

МСФ на ЯМ
Close metadata
Recommended articles:
Dyna­mics of outpatient glycemic profile data in patients with type 2 diabetes receiving dietary fiber. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):55-65
Macrovascular and microvascular complications of type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(8):94-100
Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chro­nic kidney disease. Russian Journal of Preventive Medi­cine. 2024;(8):114-120
Continuum of type 2 diabetes mellitus and its como­rbidity with other soma­tic diseases. Russian Journal of Preventive Medi­cine. 2024;(9):123-129
Modu­lation of oxidative stress as an early symptom of sarcopenia in type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2024;(10):108-116
Rela­tionship between meta­bolic syndrome components and pathology of the red border of the lips and oral mucosa. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(4-2):58-63
Classical and new athe­rosclerosis biomarkers in elde­rly patients with type 2 diabetes mellitus. Russian Journal of Preventive Medi­cine. 2025;(3):87-95

Well-timed, effective, and safe therapy of type 2 diabetes mellitus (DM2) is a challenging problem for public healthcare systems all over the world. Glibenclamide is currently the most popular sulfanylurea derivative prescribed to the patients presenting with DM2. High requirements to the safety profile of modern medications including oral hypoglycemic agents imply the necessity of close attention to the potential problems associated with the long-term application of glibennclamide. The present review is focused on the topical problems of safety and efficacy of glibenclamide arising from its use in the clinical practice.

Keywords:

glibenclamide
type 2 diabetes mellitus
sulfanylurea derivative

Authors:

Reshed'ko G.K.

GBOU VPO "Smolenskaia gosudarstvennaia meditsinskaia akademiia" Minzdravsotsrazvitiia Rossii

Khaĭkina E.V.

GBOU VPO "Smolenskaia gosudarstvennaia meditsinskaia akademiia" Minzdravsotsrazvitiia Rossii

List of references:

  1. Nathan D.M., Buse J.B., Davidson M.B. et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32 (1): 193-203.
  2. Ushkalova E.A. Sovremennye peroral'nye sakharosnizhayushchie preparaty: vnimanie k glibenklamidu. Ter arkh 2007; 12: 86-90.
  3. Nedosugova L.V. Glibenklamid - profil' effektivnosti i bezopasnosti. Sakharnyi diabet 2011; 3: 85-90.
  4. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 2003; 19 (7): 635-641.
  5. Ashcroft F.M., Gribble F.M. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabet Complicat 2000; 14 (4): 192-196.
  6. Gribble F.M., Ashcroft F.M. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000; 49 (10 Suppl 2): 3-6.
  7. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287 (3): 360-372.
  8. Müller G., Wied S., Wetekam E.M. at al. Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulphonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade. Biochem Pharmacol 1994; 48 (5): 985-996.
  9. Fukuen S., Iwaki M., Yasui A. et al. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 2005; 280 (25): 23653-23659.
  10. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of coplications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
  11. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281 (21): 2005-2012.
  12. Holman R.R., Paul S.K., Bethel M.A. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359 (15): 1577-1589.
  13. Stephan D., Winkler M., Kühner P. et al. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels. Diabetologia 2006; 49 (9): 2039-2048.
  14. Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007; 30 (2): 389-394.
  15. Zilov A.V., Morgunova T.B., Terekhova A.L. Chastota gipoglikemii i serdechno-sosudistykh narushenii na fone terapii preparatami sul'fonilmocheviny po sravneniyu s drugimi sekretagogami: sistematicheskii obzor. Sakharnyi diabet 2010; 2: 85-90.
  16. Davis T.M., Parsons R.W., Broadhurst R.J. et al. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care 1998; 21 (4): 637-640.
  17. Meier J.J., Deifuss S., Klamann A. et al. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabetes 2003; 111 (6): 344-350.
  18. Riveline J.P., Danchin N., Ledru F. et al. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003; 29 (3): 207-222.
  19. Steven E. Kahn, M.B., Ch.B., Steven M. Haffner, M.D., Mark A. et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med 2006; 355: 2427-2443.
  20. Shimabukuro M., Higa N., Takasu N. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study. J Diabet Complicat 2006; 20 (3): 179-183.
  21. Pantalone K.M., Kattan M.W., Yu C. at al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care 2010; 33 (6): 1224-1229.
  22. Karpov O.I. Mikronizirovannyi glibenklamid - modifikatsiya lekarstvennoi formy i kinetiki, natselennaya na rezul'tat. Rus med zhurn 2006; 26: 3-6.
  23. Carlson R.F., Isley W.L., Ogrinc F.G., Klobucar T.R. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. Clin Ther 1993; 15 (5): 788-796.
  24. Kunte H., Schmidt S., Eliasziw M., del Zoppo G.J., Simard J.M., Masuhr F., Weih M., Dirnagl U. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007; 38 (9): 2526-2530.
  25. Ting H.J., Khasawneh F.T. Glybenclamide: an antidiabetic with in vivo antithrombotic activity. Eur J Pharmacol 2010; 649 (1-3): 249-254.
  26. Ramsdell J.W., Braunstein S.N., Stephens J.M. et al. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. Pharmacoeconomics 2003; 21 (11): 819-837.
  27. Klarenbach S., Cameron C., Singh S., Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ 2011; 183 (16): E1213-E1220.
  28. Orales Antidiabetikum ausgezeichnet. Klinikartz 2010; 39 (9): 423.
  29. Rasporyazhenie Pravitel'stva Rossiiskoi Federatsii ot 30 dekabrya 2009 g. №2135-r g. Moskva. Dostupno na http://www.rg.ru/2010/01/13/perechenlek-dok.html
  30. Standart spetsializirovannoi meditsinskoi pomoshchi bol'nym insulinnezavisimym sakharnym diabetom. Dostupno na http://www.minzdravsoc.ru/docs/mzsr/standards/projects/34

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.